HEC Group and Wuhan Institute of Virology, Chinese Academy of Sciences have reached a strategic cooperation
2022-01-15
On January 14, HEC Group and Wuhan Institute of Virology, Chinese Academy of Sciences formally signed a cooperation agreement. The two parties reached a strategic cooperation on jointly carrying out scientific and technological research in the fields of emerging, emergent and major infectious diseases and biosafety, jointly promoting the transformation of scientific and technological achievements, and realizing complementary advantages, resource information sharing and common development. Wang Yanyi, Director of Wuhan Institute of Virology, Chinese Academy of Sciences, Xiao Gengfu, Secretary of the Party Committee, Guan Wuxiang, Deputy Director; Zhang Yushuai, Chairman of Dongguang Group, Lu Yuxin, Rotating Chairman of the Board of Directors, and Directors Zhu Yingwei and Deng Xinhua attended the signing ceremony.
HEC Group has been deeply involved in the field of biomedicine for many years, and has built a complete system of R&D, production and sales. It is a leading enterprise in the R&D and production of anti-infective drugs in China. It has in-depth research and strong accumulation of various drug production processes such as biochemical fermentation, chemical synthesis, and biological products, and has built the world's largest production base of macrolide antibiotics, the largest production base of anti-influenza drug oseltamivir phosphate in the country, and a production base of biological products such as insulin with advanced technology and complete product line. At present, relying on the State Key Laboratory of New Anti-infective Drugs of the Group Research Institute, HEC has deployed 6 anti-infective compounds with different mechanisms of action. Among them, the first completely self-developed new anti-hepatitis C drug in China, Emitasvir, has been launched in 2020. Mofexidine, the first small molecule compound that has been clinically proven to clearly inhibit HBV s antigen, has entered clinical phase 3.
Wuhan Institute of Virology, Chinese Academy of Sciences is a comprehensive research institution specializing in basic virology research and related technological innovation. Relying on high-level biosafety laboratories, it focuses on clarifying cutting-edge scientific issues related to highly pathogenic viruses, and develops prevention and control technologies and research and development of products, and systematically improves the emergency response capabilities of emerging infectious diseases. It has a number of top-level research technology platforms, such as my country's first biosafety (level 4) laboratory officially put into operation, the "National Virus Resource Bank" designated by the Ministry of Science and Technology and the Ministry of Finance, and the "National Virus Resource Bank" designated by the Ministry of Science and Technology and the Ministry of Finance, the "National Collection Center" designated by the National Health Commission of the People's Republic of China for the collection of microbial strains, National African Swine Fever Regional Laboratory, State Key Laboratory of Virology (jointly established with Wuhan University), Sino-Dutch-France Joint Open Laboratory of Invertebrate Virology, Key Laboratory of Highly Pathogenic Pathogen Biology and Biosafety of the Chinese Academy of Sciences, and the Hubei Provincial Viral Disease Engineering Technology Research Center. The conclusion of the cooperation between the two parties will establish a market-oriented technological innovation system with deep integration of production and research that meets the health needs of the country and the people, which will effectively promote scientific and technological problems and the transformation of achievements, so as to achieve sharing and win-win results.
In the future, HEC Pharma will focus on three major areas: anti-infection, tumor and metabolism. Through resource integration, a comprehensive listed pharmaceutical group integrating R&D, production and sales is formed; through the model of independent R&D industrialization and foreign cooperation introduction, it provides the company with blockbuster products with major market demand, and maintains the company's rapid and sustainable development. continuous development. From 2022 to 2026, the pharmaceutical industry of HEC will be in a period of rapid development. It is expected that the sales will exceed 26 billion yuan and the market value will exceed 100 billion yuan, making it a world-class pharmaceutical company.
Related news
2022-10-22
WeChat public account
2022 Copyright by HEC Group 粤ICP备19034764号-1